Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

SRENOL 10.9 7.0 56% 1% Other 11.7 10.9 7% 1% Total royalties 62.8 76.5 -18% 6% Other revenues 4.9 3.5 40% <1% Total Revenues 1,086.1 874.3 24% 100%

Unaudited US GAAP results for the nine months to September 30, 2011

Selected Notes to the Financial Statements

(2)  Analysis of revenues

9 months to September 30, 2011 2010 2011 2011 % % of total $M $M change Revenue Net product sales: SP ADHD VYVANSE 587.9 453.6 30% 19% ADDERALL XR 408.0 271.9 50% 13% INTUNIV 157.6 123.0 28% 5% EQUASYM 15.6 16.3 -4% <1% DAYTRANA - 49.4 n/a n/a 1,169.1 914.2 28% 37% GI LIALDA/MEZAVANT 276.0 209.2 32% 9% PENTASA 186.2 175.9 6% 6% RESOLOR 4.0 - n/a <1% 466.2 385.1 21% 15% General products FOSRENOL 127.0 137.4 -8% 4% XAGRID 69.2 65.4 6% 2% CARBATROL 45.6 63.4 -28% 2% 241.8 266.2 -9% 8% Other product sales 71.7 80.2 -11% 2% Total SP product sales 1,948.8 1,645.7 18% 62% HGT REPLAGAL 354.3 242.0 46% 11% ELAPRASE 340.9 297.4 15% 11% VPRIV 186.9 84.0 123% 6% FIRAZYR 18.1 7.7 135% 1% Total HGT product sales 900.2 631.1 43% 29% RM DERMAGRAFT 52.0 - n/a 2% Total RM product sales 52.0 - n/a 2% Total product sales 2,901.0 2,276.8 27% 93% Royalties: ADDERALL XR 66.6 86.3 -23% 2% 3TC and ZEFFIX 64.1 115.3 -44% 2% FOSRENOL 31.4 18.0 74% 1% Other 37.7 34.9 8% 1% Total royalties 199.8 254.5 -21% 6% Other revenues 20.4 8.6 137% 1% Total Revenues 3,121.2 2,539.9 23% 100%

Unaudited results for the three months to September 30, 2011

Non GAAP reconciliation

US GAAP Adjustments Non GAAP Acquisitions Divestments, Amortization & reorganizations Sept & asset integration & discontinued Reclas September 3 months to, 30, impair activities operations -sify 30, 2011 -ments depreciation 2011 (a) (b) (c) (d) $M $M $M $M $M $M Total revenues 1,086.1 - - - - 1,086.1 Costs and expenses: Cost of product sales 166.5 - (9.0) (3.4) (8.6) 145.5 Research and development 201.5 (16.0) - - (5.6)
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Smith & Nephew (LSE:SN, ... technology business, today announced its entry into the ... Lesser Toe Repair System. Comprised of three separate ... metatarsophalangeal (MTP) ligament repair and reconstruction, a metatarsal ... proximal Inter-phalanges (PIP) fusion, also known as hammer ...
(Date:7/31/2014)... 2014 Although RNA-Sequencing is a ... transcriptome-wide analyses appearing around 2008, RNA-Sequencing has rapidly ... measurement. In the last several years, assays have ... with smaller input amounts, process degraded RNA, and ... On the bioinformatics side, there have been improvements ...
(Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 ... ) finds itself flush with innovative adult stem cell ... patents and has three additional patent applications ... Office. , The patented inventions address two of the ... and regenerative medicine. Adult stem cells are difficult ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... aims to reach five million in five years, ... DGX ), the nation,s leading provider of diagnostic,testing information ... designed to help increase compliance with take-home colorectal,screening tests. ... Have,the Guts?," the campaign aims to break down barriers ...
... To Be Held Tuesday, April 1, 2008 At 10:00 a.m. Eastern ... ... March 31 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reported ... highlights., (Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO ), "2007 was a ...
... ... 31 Cephalon, Inc.,(Nasdaq: CEPH ) has scheduled its regular quarterly earnings conference call,covering first ... ... Q1 2008 results will be distributed by PRNewswire 4:50 p.m. EDT To ...
Cached Biology Technology:Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 2Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 3Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 4Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 2Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 3Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 4Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 5Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 6Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 7Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 8Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 9Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 10
(Date:7/31/2014)... same week that the U.S. surgeon general issued a ... at Montana State University published a paper breaking new ... every cell responds when exposed to ultraviolet (UV) ... damage by the UV rays found in sunlight. This ... degenerative eye diseases. , "Our paper advances foundational ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
(Date:7/30/2014)... is paving the way for a breakthrough that ... troops exposed to poisonous chemicalsparticularly those in pesticides ... the current issue of the journal ChemBioChem ... are compounds commonly used in pesticides and warfare ... School of Engineering Associate Professor of Chemical and ...
Breaking Biology News(10 mins):New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3Hope for the overweight 2Engineering a protein to prevent brain damage from toxic agents 2
... The death of insulin-producing beta cells in the pancreas ... Texas now have discovered a new way that these cells ... other pancreatic cells. "Our study shows that neighboring cells ... This was an unexpected finding," said Franco Folli, M.D., Ph.D., ...
... (NIFA) has awarded a consortium of land-grant institutions in ... Coordinated Agricultural Grant to study the effects of climate ... announcement, Paul Winistorfer, dean of the College of Natural ... climate change mitigation and adaptation as it relates to ...
... to increased well-being in adulthood, new research finds. ... childhood and mental health problems, but little research has examined ... time, researchers from the University of Cambridge and the MRC ... between a positive adolescence and well-being in midlife. Using ...
Cached Biology News:Scientists find a new way insulin-producing cells die 2Virginia Tech shares in grant to study effects of climate change on southern pine forests 2Virginia Tech shares in grant to study effects of climate change on southern pine forests 3Virginia Tech shares in grant to study effects of climate change on southern pine forests 4Happy children make happy adults 2
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning ...
...
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: